Matthew A. Gubens, MD, MS, FASCO - Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NCG865. CME/MOC/AAPA/IPCE credit will be available until December 29, 2024. Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. SupportThis activity is supported by an independent educational grant from AstraZeneca. Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner DisclosuresChair/PlannerMatthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; Invitae Corporation; iTeos Therapeutics; Merus; Sanofi; Summit; and Surface.Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell. Research funding to institution. Faculty/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc. Faculty/PlannerElaine Shum, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Genentech, Inc.; Gilead Sciences, Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from DELFI Diagnostics. Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.